Drug Screening Market Players:
- Quest Diagnostics
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Laboratory Corporation of America Holdings (LabCorp)
- Thermo Fisher Scientific
- Alere Inc.
- Siemens Healthineers
- Shimadzu Corporation
- F. Hoffmann-La Roche AG
- Express Diagnostics International Inc.
- OraSure Technologies
- Drägerwerk AG & Co. KGaA
- Sterling Check Corp.
The market is enhancing its offerings with the integration of advanced technologies and R&D participation of key players. They are continuously improving their portfolio to outperform competitors, showcasing a healthy business flow and innovation cohort in this field. For instance, in February 2025, Profacgen introduced its new ion channel testing services, including high-throughput detection and automated electrophysiology, to streamline drug development. This pipeline is crafted to assist pharma developers mitigate challenges in the research and formulation by providing accurate detection for high-expression cell lines and neurons. Such key players are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of drug screening is assessed at USD 11.1 billion.
The global drug screening market size was valued at over USD 9.76 billion in 2025 and is expected to expand at a CAGR of over 15.2%, surpassing USD 40.18 billion revenue by 2035.
The North America drug screening market is projected to capture a 35% share by 2035, driven by the increasing number of SUD-related accidents and government funding in the region.
Key players in the market include Quest Diagnostics, Laboratory Corporation of America Holdings (LabCorp), Thermo Fisher Scientific, Alere Inc., Siemens Healthineers, Shimadzu Corporation, F. Hoffmann-La Roche AG, Express Diagnostics International Inc., OraSure Technologies, Drägerwerk AG & Co. KGaA.
